Small HIV study tests safety of Virus-Waking drugs
NCT ID NCT05230368
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested whether a combination of two HIV-1 activators is safe for people with HIV subtype B who are on standard antiretroviral therapy and have undetectable virus levels. Nine men participated, and the study focused on tracking side effects. The goal was to gather safety data, not to treat or cure HIV.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION, SUBTYPE B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Antoine CHERET
Le Kremlin-Bicêtre, 94275, France
-
CHU Saint-Pierre
Brussels, 1000, Belgium
-
LAMBOTTE Olivier
Le Kremlin-Bicêtre, 94276, France
-
Odile LAUNAY
Paris, 75000, France